Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mereo BioPharma Group plc

http://mereobiopharma.com/

Latest From Mereo BioPharma Group plc

Ultragenyx Data De-Risk Phase III Trial Of Setrusumab

The Mereo-partnered drug is in pivotal development for osteogenesis imperfecta. Ultragenyx also recently reported positive Phase III data for a rare disease gene therapy.

Clinical Trials Drug Approval Standards

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.

Financing StartUps and SMEs

Sanofi Ramps Up In Rare Diseases With Inhibrx Buy

The French major is paying up to $2.2bn to get access to Inhibrx’s alpha-1 antitrypsin deficiency candidate and to take a stake in the rest of the California-based biotech’s portfolio.

M & A Rare Diseases

Will Anti-TIGITs Prove Their Value in 2023?

The promise of TIGIT as an oncology target in combination with PD-1/PD-L1 inhibitors has prompted an influx of investment into anti-TIGIT agents and five agents are already in advanced clinical trials. That initial enthusiasm has been dampened as of late, after disappointing Phase III data. Investors are hoping that 2023 will be the year that restores hope in the anti-TIGIT pipeline. 

Market Snapshot ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Mereo BioPharma Group Ltd.
    • Mereo BioPharma Group plc (MPH:LN)
    • OncoMed Pharmaceuticals, Inc. (OMED)
UsernamePublicRestriction

Register